These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21477998)

  • 1. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study.
    Arango C; Bobes J; Kirkpatrick B; Garcia-Garcia M; Rejas J
    Eur Neuropsychopharmacol; 2011 Dec; 21(12):867-75. PubMed ID: 21477998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study.
    Arango C; Bobes J; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2008 Sep; 104(1-3):1-12. PubMed ID: 18606526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.
    Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2007 Feb; 90(1-3):162-73. PubMed ID: 17123783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan.
    Huang MC; Lu ML; Tsai CJ; Chen PY; Chiu CC; Jian DL; Lin KM; Chen CH
    Acta Psychiatr Scand; 2009 Oct; 120(4):274-80. PubMed ID: 19426161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study.
    Rejas J; Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M
    Schizophr Res; 2008 Feb; 99(1-3):23-8. PubMed ID: 18063343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database.
    Sicras A; Rejas J; Navarro R; Serrat J; Blanca M
    Bipolar Disord; 2008 Jul; 10(5):607-16. PubMed ID: 18657245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands.
    Sánchez-Araña Moreno T; Touriño González R; Hernández Fleta JL; León Pérez P
    Actas Esp Psiquiatr; 2007; 35(6):359-67. PubMed ID: 18004674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes.
    Tong PC; Kong AP; So WY; Yang X; Ho CS; Ma RC; Ozaki R; Chow CC; Lam CW; Chan JC; Cockram CS
    Diabetes Care; 2007 May; 30(5):1206-11. PubMed ID: 17259472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic risk factors in drug-naive patients with first-episode psychosis.
    Verma SK; Subramaniam M; Liew A; Poon LY
    J Clin Psychiatry; 2009 Jul; 70(7):997-1000. PubMed ID: 19497246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
    Kagal UA; Torgal SS; Patil NM; Malleshappa A
    J Pharm Pract; 2012 Jun; 25(3):368-73. PubMed ID: 22551560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study.
    Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Eur Psychiatry; 2012 May; 27(4):267-74. PubMed ID: 21036549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia.
    Saddichha S; Vishnuvardhan G; Akhtar S
    Int J Risk Saf Med; 2011; 23(3):181-5. PubMed ID: 22020398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of cardiometabolic risk factors and the ten-year risk of fatal cardiovascular events in patients with schizophrenia and related psychotic disorders.
    Protopopova D; Masopust J; Maly R; Valis M; Bazant J
    Psychiatr Danub; 2012 Sep; 24(3):307-13. PubMed ID: 23013637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the metabolic syndrome on the patients with acute coronary syndrome.
    Agoşton-Coldea L; Mocan T; Rusu LD; Pais R; Albu A; Rusu ML; Perna S
    Rom J Intern Med; 2008; 46(1):55-62. PubMed ID: 19157271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
    Tirupati S; Chua LE
    Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.